
In addition to being based on a very small sample size, a recently published study on hospital costs for clinician-administered drugs under Medicare Part B does not provide direct insight as to what hospitals actually pay to acquire these drugs, writes Aaron Wesolowski, vice president of policy research, analytics and strategy at AHA.